Clinical Trial Update: An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy, safety, tolerability, immunogenicity, and lot-consistency of a 6-valent OspA-based Lyme disease vaccine (VLA15) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Disease

Drugs mentioned

• VLA15

Snippet

Sponsor: Pfizer | Conditions: Lyme Disease | Phase 3 | Status: COMPLETED